Rethinking Wellness

Rethinking Wellness

Share this post

Rethinking Wellness
Rethinking Wellness
Link Roundup: When Will the GLP-1 Hype Bubble Burst? Plus...

Link Roundup: When Will the GLP-1 Hype Bubble Burst? Plus...

“Doing your own research,” why sugar doesn’t “feed” cancer, and more.

Christy Harrison, MPH, RD's avatar
Christy Harrison, MPH, RD
Sep 26, 2024
∙ Paid
14

Share this post

Rethinking Wellness
Rethinking Wellness
Link Roundup: When Will the GLP-1 Hype Bubble Burst? Plus...
2
Share

Welcome to another installment of the Rethinking Wellness link roundup! Every other week, I’m offering a small collection of links from around the internet that are relevant to the conversations we have here, along with some quick takes and occasional deeper dives for paid subscribers.

This time it’s just one very deep (or at least very long) dive attempting to answer the question: when will the GLP-1 hype bubble burst?

Links

Here are some pieces that got me thinking this month. I generally enjoyed all of these, but links are not endorsements of every single detail in the piece or everything the writer ever wrote.

Doing Your Own Research? (

Dr. Jen Gunter
)

Is Overeaters Anonymous a Diet? (

Virginia Sole-Smith
)

Why wellness salesmen get history wrong (

Derek Beres
)

Dig into dread (

Pooja Lakshmin MD
)

Dear Surgeon General (

Melinda Wenner Moyer
)

Sugar doesn’t cause—or feed—cancer (

Dr. Andrea Love
)

In Case You Missed It

Why Smart People Fall for Wellness Misinformation (Part 1)

Exposing the Dangers of MLMs in Diet and Wellness Culture with Kat Garcia-Benson


Take/Dive

When Will the GLP-1 Hype Bubble Burst?

I came across a recent article claiming that Ozempic might actually be something like a cure-all, despite the fact that other things positioned as a panacea usually turn out to be snake oil. I thought this article was interesting in an alarming kind of way, in that we as a society are encouraging people to take a drug that clearly affects brain functions without fully understanding what it does. I'm also very skeptical of what the author is saying because, as he points out in the first paragraph of his article (and then promptly ignores), no drugs developed to date have such a positively skewed risk-benefit profile. I wonder what your thoughts are in regard to GLP-1 agonists as the newest ‘wonder drug’ hype. How long do you think before we start seeing the other side of the risk profile for them, and then how long until we as a society admit to ourselves we were wrong?

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Food Psych Programs, Inc. | Artwork by Tara Jacoby.
Publisher Privacy ∙ Publisher Terms
Substack
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share